Accelerate Diagnostics Preliminary Q4 Revenues Down 11 Percent

Jan 12, 2021

|

NEW YORK – Antibiotic resistance testing firm Accelerate Diagnostics said on Tuesday that its preliminary Q4 2020 revenue dropped 11 percent year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Accelerate Diagnostics Preliminary Q4 Revenues Down 11 Percent

To read the full story....

Breaking News

Biden Administration Funds $1B for COVID-19 Testing in Indian Country

Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

NIH Awards Qorvo Biotechnologies $24.4M for Rapid SARS-CoV-2 Antigen Test

In Brief This Week: Exact Sciences, Siemens Healthineers, Seegene, Agilent Technologies, and More

Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

What's Popular?

Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

Cancer Dx Firm C2i Genomics Raises $100M in Financing

Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

Thermo Fisher Scientific to Acquire Contract Research Organization PPD for $17.4B

Sponsorships